Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P51157
UPID:
RAB28_HUMAN
Alternative names:
-
Alternative UPACC:
P51157; G8JLC5; Q8IYR8; Q8NI05
Background:
Ras-related protein Rab-28, encoded by the gene with accession number P51157, plays a crucial role in cellular processes. Although its specific functions are yet to be fully elucidated, its involvement in the cellular machinery underscores its importance in maintaining cellular integrity and function.
Therapeutic significance:
Ras-related protein Rab-28 has been linked to Cone-rod dystrophy 18, a retinal dystrophy characterized by early loss of vision due to degeneration of cone photoreceptors. Understanding the role of Ras-related protein Rab-28 could pave the way for novel therapeutic strategies targeting this debilitating disease.